161 related articles for article (PubMed ID: 33558711)
1. Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore.
Laas E; Labrosse J; Hamy AS; Benchimol G; de Croze D; Feron JG; Coussy F; Balezeau T; Guerin J; Lae M; Pierga JY; Reyal F
Br J Cancer; 2021 Apr; 124(8):1421-1427. PubMed ID: 33558711
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Steenbruggen TG; van Seijen M; Janssen LM; van Ramshorst MS; van Werkhoven E; Vrancken Peeters MTDF; Wesseling J; Lips EH; Sonke GS
Clin Cancer Res; 2019 Aug; 25(16):4985-4992. PubMed ID: 31076546
[TBL] [Abstract][Full Text] [Related]
3. Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.
Hamy AS; Lam GT; Laas E; Darrigues L; Balezeau T; Guerin J; Livartowski A; Sadacca B; Pierga JY; Vincent-Salomon A; Coussy F; Becette V; Bonsang-Kitzis H; Rouzier R; Feron JG; Benchimol G; Laé M; Reyal F
Breast Cancer Res Treat; 2018 Jun; 169(2):295-304. PubMed ID: 29374852
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.
Kantor O; Laws A; Pastorello RG; King C; Wong S; Dey T; Schnitt S; King TA; Mittendorf EA
Ann Surg Oncol; 2021 Nov; 28(12):7347-7355. PubMed ID: 33956276
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
Hamy AS; Darrigues L; Laas E; De Croze D; Topciu L; Lam GT; Evrevin C; Rozette S; Laot L; Lerebours F; Pierga JY; Osdoit M; Faron M; Feron JG; Laé M; Reyal F
PLoS One; 2020; 15(6):e0234191. PubMed ID: 32579551
[TBL] [Abstract][Full Text] [Related]
6. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
7. Assessment of residual cancer burden and survival in neoadjuvant chemotherapy of inoperable stage III breast cancer: A ten-year follow-up analysis in Vietnam.
Pham HK; Le TD; Nguyen TP; Le TU; Ta HH; Nguyen VC
Pathol Res Pract; 2024 Feb; 254():155099. PubMed ID: 38244433
[TBL] [Abstract][Full Text] [Related]
8. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
9. Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy.
Hasegawa Y; Matsubara N; Kogawa T; Naito Y; Harano K; Hosono A; Onishi T; Hojo T; Shimokawa M; Mukohara T
In Vivo; 2021; 35(2):1041-1049. PubMed ID: 33622900
[TBL] [Abstract][Full Text] [Related]
10. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Resende U; Cabello C; Ramalho SOB; Zeferino LC
BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
[TBL] [Abstract][Full Text] [Related]
11. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Noda S; Takashima T; Onoda N; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
BMC Cancer; 2017 Dec; 17(1):888. PubMed ID: 29282021
[TBL] [Abstract][Full Text] [Related]
12. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Yau C; Osdoit M; van der Noordaa M; Shad S; Wei J; de Croze D; Hamy AS; Laé M; Reyal F; Sonke GS; Steenbruggen TG; van Seijen M; Wesseling J; Martín M; Del Monte-Millán M; López-Tarruella S; ; Boughey JC; Goetz MP; Hoskin T; Gould R; Valero V; Edge SB; Abraham JE; Bartlett JMS; Caldas C; Dunn J; Earl H; Hayward L; Hiller L; Provenzano E; Sammut SJ; Thomas JS; Cameron D; Graham A; Hall P; Mackintosh L; Fan F; Godwin AK; Schwensen K; Sharma P; DeMichele AM; Cole K; Pusztai L; Kim MO; van 't Veer LJ; Esserman LJ; Symmans WF
Lancet Oncol; 2022 Jan; 23(1):149-160. PubMed ID: 34902335
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
Symmans WF; Yau C; Chen YY; Balassanian R; Klein ME; Pusztai L; Nanda R; Parker BA; Datnow B; Krings G; Wei S; Feldman MD; Duan X; Chen B; Sattar H; Khazai L; Zeck JC; Sams S; Mhawech-Fauceglia P; Rendi M; Sahoo S; Ocal IT; Fan F; LeBeau LG; Vinh T; Troxell ML; Chien AJ; Wallace AM; Forero-Torres A; Ellis E; Albain KS; Murthy RK; Boughey JC; Liu MC; Haley BB; Elias AD; Clark AS; Kemmer K; Isaacs C; Lang JE; Han HS; Edmiston K; Viscusi RK; Northfelt DW; Khan QJ; Leyland-Jones B; Venters SJ; Shad S; Matthews JB; Asare SM; Buxton M; Asare AL; Rugo HS; Schwab RB; Helsten T; Hylton NM; van 't Veer L; Perlmutter J; DeMichele AM; Yee D; Berry DA; Esserman LJ
JAMA Oncol; 2021 Nov; 7(11):1654-1663. PubMed ID: 34529000
[TBL] [Abstract][Full Text] [Related]
14. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors.
Yi M; Lin H; Bedrosian I; Shen Y; Hunt KK; Chavez-MacGregor M; King TA; Mittendorf EA
Ann Surg Oncol; 2020 Feb; 27(2):359-366. PubMed ID: 31667721
[TBL] [Abstract][Full Text] [Related]
15. The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy.
Xu X; Zhao W; Liu C; Gao Y; Chen D; Wu M; Li C; Wang X; Song X; Yu J; Liu Z; Yu Z
BMC Cancer; 2024 Jan; 24(1):13. PubMed ID: 38166846
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
[TBL] [Abstract][Full Text] [Related]
17. Validation of the CPS+EG and Neo-Bioscore staging systems after preoperative systemic therapy for breast cancer in a single center in China.
Xu L; Duan X; Zhou B; Liu Y; Ye J; Liu Z; Ma C; Zhang H; Zhang S; Zhang L; Zhao J; Cheng Y
Breast; 2018 Aug; 40():29-37. PubMed ID: 29677568
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Bergquist JR; Murphy BL; Storlie CB; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 Nov; 24(12):3510-3517. PubMed ID: 28828583
[TBL] [Abstract][Full Text] [Related]
19. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
Mittendorf EA; Vila J; Tucker SL; Chavez-MacGregor M; Smith BD; Symmans WF; Sahin AA; Hortobagyi GN; Hunt KK
JAMA Oncol; 2016 Jul; 2(7):929-36. PubMed ID: 26986538
[TBL] [Abstract][Full Text] [Related]
20. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
Choi M; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
Breast Cancer Res Treat; 2016 Dec; 160(3):475-489. PubMed ID: 27730423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
